Therapeutic Complications in Acute Myelogenous Leukemia

Paul M. Ness, Herbert A. Perkins, Dominique J. Charron, Thierry Schmitt, Laurent Degos, Robert Peter Gale

Research output: Contribution to journalLetterpeer-review

7 Scopus citations


To the Editor: We would like to add a note of caution about platelet transfusions and alloimmunization to Dr. Gale's otherwise excellent review of acute myelogenous leukemia.1 His statement that “Most investigators believe that the frequency of alloimmunization to platelets can be decreased by the use of HLA-matched platelet donors, single-donor platelets obtained by platelet-pheresis…and autologous cryopreserved platelets” may be taken as a recommendation that all patients requiring long-term platelet support should receive only pheresis platelets. There are numerous reasons why such a recommendation should be rejected. Blood banks separate the majority of whole-blood donations into component preparations, including platelet.

Original languageEnglish (US)
Pages (from-to)557-558
Number of pages2
JournalNew England Journal of Medicine
Issue number10
StatePublished - Sep 6 1979
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Therapeutic Complications in Acute Myelogenous Leukemia'. Together they form a unique fingerprint.

Cite this